Skip to main content
This website uses cookies to ensure you get the best experience. By continuing to use this site, you agree to the use of cookies.

Please note: Your browser does not support the features used on Addgene's website. You may not be able to create an account or request plasmids through this website until you upgrade your browser. Learn more

Please note: Your browser does not fully support some of the features used on Addgene's website. If you run into any problems registering, depositing, or ordering please contact us at [email protected]. Learn more

pCVL SFFV d14GFP Donor Citations (9)

Originally described in: Tracking genome engineering outcome at individual DNA breakpoints.
Certo MT, Ryu BY, Annis JE, Garibov M, Jarjour J, Rawlings DJ, Scharenberg AM Nat Methods. 2011 Jul 10;8(8):671-6. doi: 10.1038/nmeth.1648.
PubMed Journal

Articles Citing pCVL SFFV d14GFP Donor

Articles
Design and analysis of site-specific single-strand nicking endonucleases for gene correction. Metzger MJ, Certo MT. Methods Mol Biol. 2014;1114:237-44. doi: 10.1007/978-1-62703-761-7_15. PubMed
Fanconi anemia gene editing by the CRISPR/Cas9 system. Osborn MJ, Gabriel R, Webber BR, DeFeo AP, McElroy AN, Jarjour J, Starker CG, Wagner JE, Joung JK, Voytas DF, von Kalle C, Schmidt M, Blazar BR, Tolar J. Hum Gene Ther. 2015 Feb;26(2):114-26. doi: 10.1089/hum.2014.111. PubMed
Multimode drug inducible CRISPR/Cas9 devices for transcriptional activation and genome editing. Lu J, Zhao C, Zhao Y, Zhang J, Zhang Y, Chen L, Han Q, Ying Y, Peng S, Ai R, Wang Y. Nucleic Acids Res. 2018 Mar 16;46(5):e25. doi: 10.1093/nar/gkx1222. PubMed

Associated Plasmids

Multiple Chemical Inducible Tal Effectors for Genome Editing and Transcription Activation. Zhao C, Zhang Y, Zhao Y, Ying Y, Ai R, Zhang J, Wang Y. ACS Chem Biol. 2018 Mar 16;13(3):609-617. doi: 10.1021/acschembio.7b00606. Epub 2018 Jan 8. PubMed

Associated Plasmids

HIT-Cas9: A CRISPR/Cas9 Genome-Editing Device under Tight and Effective Drug Control. Zhao C, Zhao Y, Zhang J, Lu J, Chen L, Zhang Y, Ying Y, Xu J, Wei S, Wang Y. Mol Ther Nucleic Acids. 2018 Dec 7;13:208-219. doi: 10.1016/j.omtn.2018.08.022. Epub 2018 Sep 1. PubMed

Associated Plasmids

The Chromatin Structure of CRISPR-Cas9 Target DNA Controls the Balance between Mutagenic and Homology-Directed Gene-Editing Events. Janssen JM, Chen X, Liu J, Goncalves MAFV. Mol Ther Nucleic Acids. 2019 Jun 7;16:141-154. doi: 10.1016/j.omtn.2019.02.009. Epub 2019 Feb 20. PubMed
Marker-free quantification of repair pathway utilization at Cas9-induced double-strand breaks. Feng W, Simpson DA, Cho JE, Carvajal-Garcia J, Smith CM, Headley KM, Hathaway N, Ramsden DA, Gupta GP. Nucleic Acids Res. 2021 May 21;49(9):5095-5105. doi: 10.1093/nar/gkab299. PubMed
A non-canonical, interferon-independent signaling activity of cGAMP triggers DNA damage response signaling. Banerjee D, Langberg K, Abbas S, Odermatt E, Yerramothu P, Volaric M, Reidenbach MA, Krentz KJ, Rubinstein CD, Brautigan DL, Abbas T, Gelfand BD, Ambati J, Kerur N. Nat Commun. 2021 Oct 27;12(1):6207. doi: 10.1038/s41467-021-26240-9. PubMed
DNA2 Nuclease Inhibition Confers Synthetic Lethality in Cancers with Mutant p53 and Synergizes with PARP Inhibitors. Folly-Kossi H, Graves JD, Garan LAW, Lin FT, Lin WC. Cancer Res Commun. 2023 Oct 16;3(10):2096-2112. doi: 10.1158/2767-9764.CRC-23-0166. PubMed

If you have published an article using this material, please email us at [email protected] to have your article added to this page.